Search Results - "Deardorff, William James"

  • Showing 1 - 16 results of 16
Refine Results
  1. 1

    Behavioral and psychological symptoms in Alzheimer's dementia and vascular dementia by Deardorff, William James, Grossberg, George T

    Published in Handbook of clinical neurology (2019)
    “…Behavioral and psychological symptoms of dementia (BPSD) are highly prevalent and represent a significant burden for patients and their caregivers. Early…”
    Get more information
    Journal Article
  2. 2

    The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer’s Disease by Deardorff, William James, Feen, Eliahu, Grossberg, George T.

    Published in Drugs & aging (01-07-2015)
    “…Current pharmacological therapy for Alzheimer’s disease (AD) includes the cholinesterase inhibitors (ChEIs) donepezil, rivastigmine, and galantamine and the N…”
    Get full text
    Journal Article
  3. 3

    Fingerstick glucose monitoring by cognitive impairment status in Veterans Affairs nursing home residents with diabetes by Nguyen, Brian, Deardorff, William James, Shi, Ying, Jing, Bocheng, Lee, Alexandra K., Lee, Sei J.

    “…Background Guidelines recommend nursing home (NH) residents with cognitive impairment receive less intensive glycemic treatment and less frequent fingerstick…”
    Get full text
    Journal Article
  4. 4

    A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine by Deardorff, William James, Grossberg, George T

    Published in Expert opinion on pharmacotherapy (01-12-2014)
    “…As a leading cause of disability, major depressive disorder (MDD) is characterized by reduced quality of life and altered functioning. Current pharmaceutical…”
    Get more information
    Journal Article
  5. 5

    Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease by Deardorff, William James, Grossberg, George T

    Published in Expert opinion on pharmacotherapy (01-09-2016)
    “…Alzheimer's disease (AD) is a slowly progressive neurodegenerative disease. Patients with severe AD often require assistance with daily functioning and have a…”
    Get more information
    Journal Article
  6. 6

    Do functional status and Medicare claims data improve the predictive accuracy of an electronic health record mortality index? Findings from a national Veterans Affairs cohort by Deardorff, William James, Jing, Bocheng, Jeon, Sun Y, Boscardin, W John, Lee, Alexandra K, Fung, Kathy Z, Lee, Sei J

    Published in BMC geriatrics (18-05-2022)
    “…Electronic health record (EHR) prediction models may be easier to use in busy clinical settings since EHR data can be auto-populated into models. This study…”
    Get full text
    Journal Article
  7. 7

    Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials by Deardorff, William James, Cenzer, Irena, Nguyen, Brian, Lee, Sei J

    Published in JAMA internal medicine (01-01-2022)
    “…The clinical decision to initiate bisphosphonate therapy for the treatment of osteoporosis requires balancing shorter-term harms and burdens (eg,…”
    Get more information
    Journal Article
  8. 8

    Mild cognitive impairment as a clinical and research outcome: Ready for prime time? by Deardorff, William James, Lee, Sei J.

    “…This editorial comments on the article by Gaussoin et al. in this issue…”
    Get full text
    Journal Article
  9. 9

    Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeutics by Deardorff, William James, Grossberg, George T

    Published in Expert review of neurotherapeutics (02-01-2017)
    “…There is an increasing recognition of the immune system as an important mediator in the pathogenesis of Alzheimer's disease (AD). As immune system modulators,…”
    Get more information
    Journal Article
  10. 10
  11. 11

    Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication by Deardorff, William James, Shobassy, Ahmad, Grossberg, George T

    Published in Expert review of neurotherapeutics (01-01-2015)
    “…Alzheimer's disease (AD) is a prevalent and currently incurable brain disease whose impact will continue to rise as the population ages. With limited treatment…”
    Get more information
    Journal Article
  12. 12
  13. 13

    Association of Sensory and Cognitive Impairment With Healthcare Utilization and Cost in Older Adults by Deardorff, William James, Liu, Phillip L., Sloane, Richard, Van Houtven, Courtney, Pieper, Carl F., Hastings, Susan Nicole, Cohen, Harvey J., Whitson, Heather E.

    “…OBJECTIVES To examine the association between self‐reported vision impairment (VI), hearing impairment (HI), and dual‐sensory impairment (DSI), stratified by…”
    Get full text
    Journal Article
  14. 14

    A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease by Deardorff, William James, Grossberg, George T

    Published in Drug design, development and therapy (01-01-2016)
    “…Currently available therapies for the treatment of Alzheimer's disease (AD) consist of cholinesterase inhibitors (ChEIs), such as donepezil, and the…”
    Get full text
    Journal Article
  15. 15

    Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease by Nieto, Rachel A, Deardorff, William James, Grossberg, George T

    Published in Expert opinion on pharmacotherapy (12-04-2016)
    “…As the most common major neurocognitive disorder, Alzheimer's disease (AD) will play an increasingly important role both socially and financially as the…”
    Get more information
    Journal Article
  16. 16

    The Pharmacology and Clinical Use of the Antidepressants Vilazodone, Levomilnacipran, and Vortioxetine for Depression in the Elderly by Deardorff, William James, Grossberg, George T.

    Published in Current geriatrics reports (01-12-2015)
    “…Treatment of depression in the elderly is particularly challenging due to the relative scarcity of well-designed trials, atypical clinical presentations, and…”
    Get full text
    Journal Article